GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shenzhen Hepalink Pharmaceutical Group Co 002399.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.32

-1.27%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥5.48bn

FY2016FY2025

Net income

CN¥349.5m

FY2016FY2025

Free cash flow

CN¥1.59bn

FY2016FY2025

Shareholders' equity

CN¥12.03bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥5.48bnCN¥5.26bnCN¥5.43bnCN¥7.16bnCN¥6.37bnCN¥5.33bnCN¥4.62bnCN¥4.81bnCN¥2.84bnCN¥2.26bn
Gross profitCN¥1.74bnCN¥1.74bnCN¥940.9mCN¥2.30bnCN¥2.00bnCN¥2.03bnCN¥1.68bnCN¥1.88bnCN¥862.9mCN¥697.5m
Research and developmentCN¥226.2mCN¥212.0mCN¥182.4mCN¥252.1mCN¥221.1mCN¥160.0mCN¥148.7mCN¥186.5mCN¥93.5mCN¥62.0m
Operating incomeCN¥636.0mCN¥616.2m−CN¥729.2mCN¥1.03bnCN¥227.5mCN¥1.33bnCN¥1.55bnCN¥850.5mCN¥92.2mCN¥435.6m
Net incomeCN¥349.5mCN¥646.7m−CN¥783.3mCN¥727.4mCN¥240.8mCN¥1.02bnCN¥1.06bnCN¥591.5mCN¥196.7mCN¥396.9m
Diluted earnings per share0.240.44-0.520.490.160.670.850.470.160.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥16.63bnCN¥17.34bnCN¥19.20bnCN¥20.81bnCN¥19.11bnCN¥19.03bnCN¥15.24bnCN¥13.66bnCN¥13.19bnCN¥12.91bn
Cash and short-term investments—CN¥2.56bnCN¥2.27bnCN¥3.45bnCN¥3.93bnCN¥3.54bnCN¥1.39bnCN¥2.20bnCN¥3.50bnCN¥4.56bn
Total liabilitiesCN¥4.55bnCN¥5.14bnCN¥7.22bnCN¥8.41bnCN¥7.58bnCN¥7.34bnCN¥7.77bnCN¥7.41bnCN¥5.50bnCN¥4.83bn
DebtCN¥298.1mCN¥2.98bnCN¥5.56bnCN¥6.46bnCN¥5.65bnCN¥5.65bnCN¥6.30bnCN¥4.92bnCN¥4.71bnCN¥3.89bn
Shareholders' equityCN¥12.03bnCN¥12.15bnCN¥11.91bnCN¥12.31bnCN¥11.41bnCN¥11.57bnCN¥7.35bnCN¥6.07bnCN¥7.58bnCN¥7.97bn
Shares outstanding1,467m1,478m1,511m1,470m1,467m1,525m1,247m1,247m1,249m1,218m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.71bnCN¥2.19bnCN¥398.2m−CN¥756.6m−CN¥6.6mCN¥37.3m−CN¥227.6mCN¥667.9m−CN¥407.1mCN¥346.1m
Capital spending−CN¥121.1m−CN¥202.8m−CN¥444.9m−CN¥222.4m−CN¥193.9m−CN¥212.5m−CN¥362.1m−CN¥535.0m−CN¥576.1m−CN¥359.5m
Free cash flowCN¥1.59bnCN¥1.99bn−CN¥46.7m−CN¥979.0m−CN¥200.5m−CN¥175.2m−CN¥589.7mCN¥132.9m−CN¥983.2m−CN¥13.5m
Dividends paid−CN¥430.8m−CN¥159.9m−CN¥425.9m−CN¥51.4m−CN¥220.1m−CN¥224.5m−CN¥342.5m−CN¥255.1m−CN¥444.6m−CN¥541.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.25bnCN¥1.33bnCN¥1.28bnCN¥1.38bnCN¥1.42bnCN¥1.39bnCN¥1.19bnCN¥1.23bn
Gross profitCN¥427.6mCN¥454.5mCN¥420.6mCN¥492.9mCN¥448.3mCN¥381.2mCN¥388.3mCN¥348.8m
Operating incomeCN¥137.7mCN¥202.8mCN¥104.6mCN¥159.1mCN¥322.9mCN¥179.0m−CN¥903.5mCN¥120.1m
Net incomeCN¥87.7mCN¥187.6m−CN¥204.1mCN¥131.7mCN¥265.3mCN¥156.6m−CN¥133.4mCN¥116.4m
Diluted earnings per share0.060.13-0.140.090.180.11-0.090.08
Cash from operations———CN¥399.0mCN¥504.0mCN¥544.0m—CN¥695.0m
Capital spending−CN¥18.0m−CN¥21.0m−CN¥26.0m−CN¥13.0m−CN¥39.0m−CN¥41.0m−CN¥62.0m−CN¥52.0m
Free cash flow———CN¥386.0mCN¥465.0mCN¥503.0m—CN¥643.0m
Total assetsCN¥16.31bnCN¥17.01bnCN¥16.63bnCN¥17.13bnCN¥17.23bnCN¥17.55bnCN¥17.34bnCN¥18.12bn
Cash and short-term investments———CN¥3.08bnCN¥3.06bnCN¥3.10bnCN¥2.56bnCN¥3.08bn
DebtCN¥27.5mCN¥28.7mCN¥298.1mCN¥2.61bnCN¥2.33bnCN¥2.80bnCN¥2.92bnCN¥4.25bn
Shareholders' equityCN¥11.93bnCN¥12.18bnCN¥12.03bnCN¥12.37bnCN¥12.16bnCN¥12.29bnCN¥12.15bnCN¥12.14bn

Financial ratios

Data as of 29 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin31.8%33.1%17.3%32.1%31.4%38.1%
Operating margin11.6%11.7%-13.4%14.4%3.6%24.9%
Net margin6.4%12.3%-14.4%10.2%3.8%19.2%
Return on equity2.9%5.3%-6.6%5.9%2.1%8.9%
Return on assets2.1%3.7%-4.1%3.5%1.3%5.4%
Free cash flow yield13.0%16.9%5.8%-3.8%1.3%1.7%
Revenue growth4.2%-3.2%-24.1%12.5%19.4%15.3%
Earnings growth-46.0%-182.6%-207.7%202.1%-76.5%-3.3%
Current ratio2.31x2.60x2.13x2.22x2.25x2.53x
Debt to equity0.02x0.24x0.46x0.51x0.36x0.43x
Equity ratio72.3%70.0%62.0%59.1%59.7%60.8%
Interest coverage8.90x4.01x-3.05x4.01x1.13x4.86x
R&D as a share of sales4.1%4.0%3.4%3.5%3.5%3.0%
Buybacks as a share of market value0.7%2.2%-2.8%-0.2%3.8%-22.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-8.5%0.5%9.1%
Operating income-14.9%-13.7%-0.1%
Net income-21.7%-19.3%-4.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.4%28.8%30.7%32.2%
Operating margin11.7%6.7%8.9%12.9%
Net margin9.3%4.0%6.3%9.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings49.524.4-22.626.0104.225.623.048.697.055.9
Price to sales3.23.03.32.63.94.95.36.06.79.8

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 7 Jul 2025.

FY2025FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Paid in the year0.250.100.0350.150.180.100.0450.25
  • 8-for-5 split · 13 Jun 2016
  • 2-for-1 split · 29 Apr 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.